These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 15546675)

  • 21. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
    Contrera JF
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical risk assessment and uncertainty associated with extrapolation across exposure duration.
    Pohl HR; Chou CH; Ruiz P; Holler JS
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):18-23. PubMed ID: 19944126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final report on the safety assessment of methoxyisopropanol and methoxyisopropyl acetate as used in cosmetics.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 2():25-39. PubMed ID: 18830862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative evaluation of US Food and Drug Administration and pharmacologically guided approaches to determine the maximum recommended starting dose for first-in-human clinical trials in adult healthy men.
    Imam MT; Venkateshan SP; Tandon M; Saha N; Pillai KK
    J Clin Pharmacol; 2011 Dec; 51(12):1655-64. PubMed ID: 21415286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of acute oral toxicity using the No Observed Adverse Effect Level (NOAEL) from the 28 day repeated dose toxicity studies in rats.
    Bulgheroni A; Kinsner-Ovaskainen A; Hoffmann S; Hartung T; Prieto P
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):16-9. PubMed ID: 18977273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection.
    Tetko IV; Sushko I; Pandey AK; Zhu H; Tropsha A; Papa E; Oberg T; Todeschini R; Fourches D; Varnek A
    J Chem Inf Model; 2008 Sep; 48(9):1733-46. PubMed ID: 18729318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative structure-activity relationship (QSAR) modeling of human blood: air partitioning with proper statistical methods and validation.
    Basak SC; Mills D; Hawkins DM; Kraker JJ
    Chem Biodivers; 2009 Apr; 6(4):487-502. PubMed ID: 19353545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An analysis of the risk of exceeding the acceptable or tolerable daily intake.
    Renwick AG; Walker R
    Regul Toxicol Pharmacol; 1993 Dec; 18(3):463-80. PubMed ID: 8128007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative approaches to human risk assessment for noncancer health effects.
    Kimmel CA
    Neurotoxicology; 1990; 11(2):189-98. PubMed ID: 2234540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute, subchronic and chronic safety studies with genistein in rats.
    Michael McClain R; Wolz E; Davidovich A; Pfannkuch F; Edwards JA; Bausch J
    Food Chem Toxicol; 2006 Jan; 44(1):56-80. PubMed ID: 16213646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data.
    Renwick AG
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S79-86. PubMed ID: 10597618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Toxicol Mech Methods; 2008; 18(2-3):207-16. PubMed ID: 20020915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting physical properties of emerging compounds with limited physical and chemical data: QSAR model uncertainty and applicability to military munitions.
    Bennett ER; Clausen J; Linkov E; Linkov I
    Chemosphere; 2009 Nov; 77(10):1412-8. PubMed ID: 19793608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.